Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-09-05), Takeda Pharmaceutical Co's 12-1 Month Momentum % is 8.31%.
The industry rank for Takeda Pharmaceutical Co's 12-1 Month Momentum % or its related term are showing as below:
TAK's 12-1 Month Momentum % is ranked better than 81.38% of 1015
companies
in the Drug Manufacturers industry
Industry Median: -15.23
vs TAK: 8.31
Takeda Pharmaceutical Co (NYSE:TAK) 12-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Takeda Pharmaceutical Co 12-1 Month Momentum % Related Terms
TAK vs ZTS: 12-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Takeda Pharmaceutical Co 12-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Takeda Pharmaceutical Co's 12-1 Month Momentum % falls into.
Takeda Pharmaceutical Co (NYSE:TAK) 12-1 Month Momentum % Calculation
12-1 Month Momentum % is calculated as following:
12-1 Month Momentum %
=
( Price 1-month ago
/
Price 12-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Takeda Pharmaceutical Co (TAK) has a 12-1 Month Momentum % of 8.31% as of Sep. 05, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Takeda Pharmaceutical Co and its competitors. According to the industry distribution chart, Takeda Pharmaceutical Co ranks #189 out of 1015 companies in the Drug Manufacturers industry, placing it in the top 18.6%.
Is Takeda Pharmaceutical Co's 12-1 Month Momentum % too high?
Takeda Pharmaceutical Co's current 12-1 Month Momentum % is 8.31%. Based on the distribution chart, Takeda Pharmaceutical Co ranks #189 out of 1015 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Takeda Pharmaceutical Co has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takeda Pharmaceutical Co's 12-1 Month Momentum % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Takeda Pharmaceutical Co ranks #189 out of 1015 companies for 12-1 Month Momentum %. This places Takeda Pharmaceutical Co in the top 19% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Drug Manufacturers company?
A good 12-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Takeda Pharmaceutical Co and its competitors. Takeda Pharmaceutical Co's current 12-1 Month Momentum % is 8.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takeda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co (TAK) is currently considered Modestly Overvalued. The stock's GF Value™ is $14.63, compared to a current price of $18.45 — trading 26.1% above its estimated fair value. The current 12-1 Month Momentum % is 8.31%. Takeda Pharmaceutical Co's overall GF Score™ is 76/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Takeda Pharmaceutical Co (TAK), the current 12-1 Month Momentum % is 8.31% as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Takeda Pharmaceutical Co (TAK) Overvalued in 2026?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co stock appears to be overvalued.
The current stock price of $18.45 is trading 26.1% above its estimated GF Value™ of $14.63.
GuruFocus considers Takeda Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for TAK:
12-1 Month Momentum %: 8.31%
GF Value™: $14.63 vs. price of $18.45 (26.1% above fair value)
No single metric tells the full story. See the TAK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
76GF Score
Get the complete analysis for TAK
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TAK has been successfully added to your 
